05.21.26 -- Gaining An Edge In GLP-1 Production

View how enzyme-driven reactions accelerate pharmaceutical ingredient manufacturing, improve selectivity, reduce waste, lower costs, and support scalable processes under mild conditions.

Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill & finish.

Chief Scientific Officer Jon Lenn discusses the balance of art and science in topical formulation development, emphasizing advanced skin models for optimized delivery, activity, and product stability.

Discover how AI-enabled digital validation shifts manufacturers from reactive compliance to predictive intelligence, connecting validation, asset, and quality data to accelerate digital maturity.

New digital tools offer life sciences manufacturers powerful ways to boost reliability and efficiency. Explore how to embrace innovation while maintaining clarity and operational focus.

Growing use of large‑volume subcutaneous therapies is increasing demand for wearable injectors that reduce user error, simplify preparation, and enhance safety through human‑factors‑focused design.

In the face of increasing molecular complexity, early developability assessment with a skilled CDMO can reduce pharmaceutical development costs, prevent clinical delays, and improve commercial success.

Compliance with EU GMP Annex 1 requires a strategic CCS. See how a framework based on people, communication, process, and continuous improvement enables systematic, long-term compliance.

Autoinjectors add mechanical forces and interactions that change how container closure integrity must be evaluated. Learn why device complexity creates new risks and how testing strategies must adapt.

Uncover how end-to-end digital twins and Integrated Process Models are transforming manufacturing to enhance flexibility, accelerate time-to-market, and enable real-time decision-making.

Industrial AI is changing how operations use data, making insights reliable, scalable, and grounded in a real manufacturing context. Find out how unified IT/OT intelligence enables predictive optimization.

Optimize biopharmaceutical manufacturing by implementing risk-based seal maintenance. Tailor replacement protocols using data and advanced monitoring for enhanced efficiency and compliance.

Despite the benefits of B/F/S over glass, some pharmaceutical companies refuse to make the switch. Examine how an investment in B/F/S may yield incredible long-term savings.

Adrulipase spray-dried dispersions were evaluated to create an orally delivered, enteric-protected enzyme. The lead formulation provided the best acid protection, rapid release, and stability.

Expression of inclusion bodies has historically suffered a bad reputation in the industry. So, how do these two routes, soluble and insoluble, compare in terms of their advantages and challenges?

Antibody-drug conjugates (ADCs) combine antibody targeting with potent cytotoxic payloads to treat resistant cancers, but their complexity requires phase-appropriate analytical strategies.